- Home
- OBT vs NGNE Comparison
OBT vs NGNE Comparison
Compare OBT & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBT
- NGNE
- Stock Information
- Founded
- OBT 1892
- NGNE 2003
- Country
- OBT United States
- NGNE United States
- Employees
- OBT N/A
- NGNE N/A
- Industry
- OBT Major Banks
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- OBT Finance
- NGNE Health Care
- Exchange
- OBT Nasdaq
- NGNE Nasdaq
- Market Cap
- OBT 294.2M
- NGNE 251.9M
- IPO Year
- OBT N/A
- NGNE N/A
- Fundamental
- Price
- OBT $23.85
- NGNE $17.86
- Analyst Decision
- OBT Buy
- NGNE Strong Buy
- Analyst Count
- OBT 1
- NGNE 7
- Target Price
- OBT $35.50
- NGNE $41.86
- AVG Volume (30 Days)
- OBT 53.8K
- NGNE 183.6K
- Earning Date
- OBT 07-30-2025
- NGNE 08-08-2025
- Dividend Yield
- OBT 2.13%
- NGNE N/A
- EPS Growth
- OBT N/A
- NGNE N/A
- EPS
- OBT 2.41
- NGNE N/A
- Revenue
- OBT $100,883,000.00
- NGNE $925,000.00
- Revenue This Year
- OBT $18.39
- NGNE N/A
- Revenue Next Year
- OBT $7.98
- NGNE N/A
- P/E Ratio
- OBT $9.74
- NGNE N/A
- Revenue Growth
- OBT N/A
- NGNE N/A
- 52 Week Low
- OBT $20.97
- NGNE $6.88
- 52 Week High
- OBT $33.06
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- OBT 45.19
- NGNE 48.91
- Support Level
- OBT $22.84
- NGNE $18.22
- Resistance Level
- OBT $24.20
- NGNE $21.43
- Average True Range (ATR)
- OBT 0.90
- NGNE 2.15
- MACD
- OBT -0.14
- NGNE -0.45
- Stochastic Oscillator
- OBT 35.07
- NGNE 19.98
About OBT Orange County Bancorp Inc.
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.